Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) in patients with Type 2 Diabetes (T2D), and reduce CV death or worsening HF in HF and reduced ejection fraction (HFrEF), regardless of T2D. Mechanisms of HF benefits are unclear, and effects of SGLT2i on filling pressures are not known. EMBRACE-HF was designed to address this knowledge gap.

Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor, Rita Jermyn, David M. Shavelle, Fengming Tang, Sumant Lamba, Kunjan Bhatt, John Brush, Andrew B. Civitello, Robert A. Gordon, Orvar Jonsson, Brent C. Lampert, Jamie Pelzel, Mikhail Kosiborod Source Type: research